Poly(I:C) Induces Human Lung Endothelial Barrier Dysfunction by Disrupting Tight Junction Expression of Claudin-5.
Identifieur interne : 000199 ( PubMed/Curation ); précédent : 000198; suivant : 000200Poly(I:C) Induces Human Lung Endothelial Barrier Dysfunction by Disrupting Tight Junction Expression of Claudin-5.
Auteurs : Li-Yun Huang [États-Unis] ; Christine Stuart [États-Unis] ; Kazuyo Takeda [États-Unis] ; Felice D'Agnillo [États-Unis] ; Basil Golding [États-Unis]Source :
- PloS one [ 1932-6203 ] ; 2016.
Descripteurs français
- KwdFr :
- ARN messager (génétique), ARN messager (métabolisme), Cellules endothéliales (cytologie), Cellules endothéliales (métabolisme), Chimiokines (métabolisme), Claudine-5 (génétique), Facteur de transcription NF-kappa B (métabolisme), Facteur-3 de régulation d'interféron (métabolisme), Humains, Jonctions serrées (), Jonctions serrées (métabolisme), Perméabilité (), Poly I-C (métabolisme), Poly I-C (pharmacologie), Poumon (cytologie), Protéines adaptatrices du transport vésiculaire (métabolisme), Récepteur de type Toll-3 (métabolisme), Régulation négative (), Transduction du signal ().
- MESH :
- cytologie : Cellules endothéliales, Poumon.
- génétique : ARN messager, Claudine-5.
- métabolisme : ARN messager, Cellules endothéliales, Chimiokines, Facteur de transcription NF-kappa B, Facteur-3 de régulation d'interféron, Jonctions serrées, Poly I-C, Protéines adaptatrices du transport vésiculaire, Récepteur de type Toll-3.
- pharmacologie : Poly I-C.
- Humains, Jonctions serrées, Perméabilité, Régulation négative, Transduction du signal.
English descriptors
- KwdEn :
- Adaptor Proteins, Vesicular Transport (metabolism), Chemokines (metabolism), Claudin-5 (genetics), Down-Regulation (drug effects), Endothelial Cells (cytology), Endothelial Cells (metabolism), Humans, Interferon Regulatory Factor-3 (metabolism), Lung (cytology), NF-kappa B (metabolism), Permeability (drug effects), Poly I-C (metabolism), Poly I-C (pharmacology), RNA, Messenger (genetics), RNA, Messenger (metabolism), Signal Transduction (drug effects), Tight Junctions (drug effects), Tight Junctions (metabolism), Toll-Like Receptor 3 (metabolism).
- MESH :
- chemical , genetics : Claudin-5, RNA, Messenger.
- chemical , metabolism : Adaptor Proteins, Vesicular Transport, Chemokines, Interferon Regulatory Factor-3, NF-kappa B, Poly I-C, RNA, Messenger, Toll-Like Receptor 3.
- cytology : Endothelial Cells, Lung.
- drug effects : Down-Regulation, Permeability, Signal Transduction, Tight Junctions.
- metabolism : Endothelial Cells, Tight Junctions.
- chemical , pharmacology : Poly I-C.
- Humans.
Abstract
Viral infections are often accompanied by pulmonary microvascular leakage and vascular endothelial dysfunction via mechanisms that are not completely defined. Here, we investigated the effect of the Toll-like receptor 3 (TLR3) ligand polyinosinic-polycytidylic acid [Poly(I:C)], a synthetic analog of viral double-stranded RNA (dsRNA) commonly used to simulate viral infections, on the barrier function and tight junction integrity of primary human lung microvascular endothelial cells. Poly(I:C) stimulated IL-6, IL-8, TNFα, and IFNβ production in conjunction with the activation of NF-κB and IRF3 confirming the Poly(I:C)-responsiveness of these cells. Poly(I:C) increased endothelial monolayer permeability with a corresponding dose- and time-dependent decrease in the expression of claudin-5, a transmembrane tight junction protein and reduction of CLDN5 mRNA levels. Immunofluorescence experiments revealed disappearance of membrane-associated claudin-5 and co-localization of cytoplasmic claudin-5 with lysosomal-associated membrane protein 1. Chloroquine and Bay11-7082, inhibitors of TLR3 and NF-κB signaling, respectively, protected against the loss of claudin-5. Together, these findings provide new insight on how dsRNA-activated signaling pathways may disrupt vascular endothelial function and contribute to vascular leakage pathologies.
DOI: 10.1371/journal.pone.0160875
PubMed: 27504984
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000199
Links to Exploration step
pubmed:27504984Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Poly(I:C) Induces Human Lung Endothelial Barrier Dysfunction by Disrupting Tight Junction Expression of Claudin-5.</title><author><name sortKey="Huang, Li Yun" sort="Huang, Li Yun" uniqKey="Huang L" first="Li-Yun" last="Huang">Li-Yun Huang</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Plasma Derivatives, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Plasma Derivatives, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="Stuart, Christine" sort="Stuart, Christine" uniqKey="Stuart C" first="Christine" last="Stuart">Christine Stuart</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Plasma Derivatives, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Plasma Derivatives, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="Takeda, Kazuyo" sort="Takeda, Kazuyo" uniqKey="Takeda K" first="Kazuyo" last="Takeda">Kazuyo Takeda</name><affiliation wicri:level="1"><nlm:affiliation>Microscopy and Imaging Core Facility, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Microscopy and Imaging Core Facility, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="D Agnillo, Felice" sort="D Agnillo, Felice" uniqKey="D Agnillo F" first="Felice" last="D'Agnillo">Felice D'Agnillo</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Biochemistry and Vascular Biology, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Biochemistry and Vascular Biology, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="Golding, Basil" sort="Golding, Basil" uniqKey="Golding B" first="Basil" last="Golding">Basil Golding</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Plasma Derivatives, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Plasma Derivatives, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27504984</idno><idno type="pmid">27504984</idno><idno type="doi">10.1371/journal.pone.0160875</idno><idno type="wicri:Area/PubMed/Corpus">000199</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000199</idno><idno type="wicri:Area/PubMed/Curation">000199</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000199</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Poly(I:C) Induces Human Lung Endothelial Barrier Dysfunction by Disrupting Tight Junction Expression of Claudin-5.</title><author><name sortKey="Huang, Li Yun" sort="Huang, Li Yun" uniqKey="Huang L" first="Li-Yun" last="Huang">Li-Yun Huang</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Plasma Derivatives, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Plasma Derivatives, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="Stuart, Christine" sort="Stuart, Christine" uniqKey="Stuart C" first="Christine" last="Stuart">Christine Stuart</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Plasma Derivatives, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Plasma Derivatives, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="Takeda, Kazuyo" sort="Takeda, Kazuyo" uniqKey="Takeda K" first="Kazuyo" last="Takeda">Kazuyo Takeda</name><affiliation wicri:level="1"><nlm:affiliation>Microscopy and Imaging Core Facility, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Microscopy and Imaging Core Facility, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="D Agnillo, Felice" sort="D Agnillo, Felice" uniqKey="D Agnillo F" first="Felice" last="D'Agnillo">Felice D'Agnillo</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Biochemistry and Vascular Biology, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Biochemistry and Vascular Biology, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland</wicri:regionArea></affiliation></author><author><name sortKey="Golding, Basil" sort="Golding, Basil" uniqKey="Golding B" first="Basil" last="Golding">Basil Golding</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Plasma Derivatives, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Plasma Derivatives, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland</wicri:regionArea></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptor Proteins, Vesicular Transport (metabolism)</term><term>Chemokines (metabolism)</term><term>Claudin-5 (genetics)</term><term>Down-Regulation (drug effects)</term><term>Endothelial Cells (cytology)</term><term>Endothelial Cells (metabolism)</term><term>Humans</term><term>Interferon Regulatory Factor-3 (metabolism)</term><term>Lung (cytology)</term><term>NF-kappa B (metabolism)</term><term>Permeability (drug effects)</term><term>Poly I-C (metabolism)</term><term>Poly I-C (pharmacology)</term><term>RNA, Messenger (genetics)</term><term>RNA, Messenger (metabolism)</term><term>Signal Transduction (drug effects)</term><term>Tight Junctions (drug effects)</term><term>Tight Junctions (metabolism)</term><term>Toll-Like Receptor 3 (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ARN messager (génétique)</term><term>ARN messager (métabolisme)</term><term>Cellules endothéliales (cytologie)</term><term>Cellules endothéliales (métabolisme)</term><term>Chimiokines (métabolisme)</term><term>Claudine-5 (génétique)</term><term>Facteur de transcription NF-kappa B (métabolisme)</term><term>Facteur-3 de régulation d'interféron (métabolisme)</term><term>Humains</term><term>Jonctions serrées ()</term><term>Jonctions serrées (métabolisme)</term><term>Perméabilité ()</term><term>Poly I-C (métabolisme)</term><term>Poly I-C (pharmacologie)</term><term>Poumon (cytologie)</term><term>Protéines adaptatrices du transport vésiculaire (métabolisme)</term><term>Récepteur de type Toll-3 (métabolisme)</term><term>Régulation négative ()</term><term>Transduction du signal ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Claudin-5</term><term>RNA, Messenger</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Adaptor Proteins, Vesicular Transport</term><term>Chemokines</term><term>Interferon Regulatory Factor-3</term><term>NF-kappa B</term><term>Poly I-C</term><term>RNA, Messenger</term><term>Toll-Like Receptor 3</term></keywords><keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Cellules endothéliales</term><term>Poumon</term></keywords><keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Endothelial Cells</term><term>Lung</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Down-Regulation</term><term>Permeability</term><term>Signal Transduction</term><term>Tight Junctions</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>ARN messager</term><term>Claudine-5</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Endothelial Cells</term><term>Tight Junctions</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>ARN messager</term><term>Cellules endothéliales</term><term>Chimiokines</term><term>Facteur de transcription NF-kappa B</term><term>Facteur-3 de régulation d'interféron</term><term>Jonctions serrées</term><term>Poly I-C</term><term>Protéines adaptatrices du transport vésiculaire</term><term>Récepteur de type Toll-3</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Poly I-C</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Poly I-C</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Jonctions serrées</term><term>Perméabilité</term><term>Régulation négative</term><term>Transduction du signal</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Viral infections are often accompanied by pulmonary microvascular leakage and vascular endothelial dysfunction via mechanisms that are not completely defined. Here, we investigated the effect of the Toll-like receptor 3 (TLR3) ligand polyinosinic-polycytidylic acid [Poly(I:C)], a synthetic analog of viral double-stranded RNA (dsRNA) commonly used to simulate viral infections, on the barrier function and tight junction integrity of primary human lung microvascular endothelial cells. Poly(I:C) stimulated IL-6, IL-8, TNFα, and IFNβ production in conjunction with the activation of NF-κB and IRF3 confirming the Poly(I:C)-responsiveness of these cells. Poly(I:C) increased endothelial monolayer permeability with a corresponding dose- and time-dependent decrease in the expression of claudin-5, a transmembrane tight junction protein and reduction of CLDN5 mRNA levels. Immunofluorescence experiments revealed disappearance of membrane-associated claudin-5 and co-localization of cytoplasmic claudin-5 with lysosomal-associated membrane protein 1. Chloroquine and Bay11-7082, inhibitors of TLR3 and NF-κB signaling, respectively, protected against the loss of claudin-5. Together, these findings provide new insight on how dsRNA-activated signaling pathways may disrupt vascular endothelial function and contribute to vascular leakage pathologies. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27504984</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>8</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Poly(I:C) Induces Human Lung Endothelial Barrier Dysfunction by Disrupting Tight Junction Expression of Claudin-5.</ArticleTitle><Pagination><MedlinePgn>e0160875</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0160875</ELocationID><Abstract><AbstractText>Viral infections are often accompanied by pulmonary microvascular leakage and vascular endothelial dysfunction via mechanisms that are not completely defined. Here, we investigated the effect of the Toll-like receptor 3 (TLR3) ligand polyinosinic-polycytidylic acid [Poly(I:C)], a synthetic analog of viral double-stranded RNA (dsRNA) commonly used to simulate viral infections, on the barrier function and tight junction integrity of primary human lung microvascular endothelial cells. Poly(I:C) stimulated IL-6, IL-8, TNFα, and IFNβ production in conjunction with the activation of NF-κB and IRF3 confirming the Poly(I:C)-responsiveness of these cells. Poly(I:C) increased endothelial monolayer permeability with a corresponding dose- and time-dependent decrease in the expression of claudin-5, a transmembrane tight junction protein and reduction of CLDN5 mRNA levels. Immunofluorescence experiments revealed disappearance of membrane-associated claudin-5 and co-localization of cytoplasmic claudin-5 with lysosomal-associated membrane protein 1. Chloroquine and Bay11-7082, inhibitors of TLR3 and NF-κB signaling, respectively, protected against the loss of claudin-5. Together, these findings provide new insight on how dsRNA-activated signaling pathways may disrupt vascular endothelial function and contribute to vascular leakage pathologies. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Li-Yun</ForeName><Initials>LY</Initials><AffiliationInfo><Affiliation>Laboratory of Plasma Derivatives, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stuart</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Plasma Derivatives, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>Kazuyo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Microscopy and Imaging Core Facility, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Agnillo</LastName><ForeName>Felice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratory of Biochemistry and Vascular Biology, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golding</LastName><ForeName>Basil</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratory of Plasma Derivatives, Division of Hematology Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033942">Adaptor Proteins, Vesicular Transport</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018925">Chemokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D062507">Claudin-5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C494232">IRF3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050838">Interferon Regulatory Factor-3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016328">NF-kappa B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C470409">TICAM1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495344">TLR3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051196">Toll-Like Receptor 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>O84C90HH2L</RegistryNumber><NameOfSubstance UI="D011070">Poly I-C</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D033942" MajorTopicYN="N">Adaptor Proteins, Vesicular Transport</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018925" MajorTopicYN="N">Chemokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062507" MajorTopicYN="N">Claudin-5</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050838" MajorTopicYN="N">Interferon Regulatory Factor-3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016328" MajorTopicYN="N">NF-kappa B</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010539" MajorTopicYN="N">Permeability</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011070" MajorTopicYN="N">Poly I-C</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019108" MajorTopicYN="N">Tight Junctions</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051196" MajorTopicYN="N">Toll-Like Receptor 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>01</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>07</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27504984</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0160875</ArticleId><ArticleId IdType="pii">PONE-D-16-03858</ArticleId><ArticleId IdType="pmc">PMC4978501</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hong Kong Med J. 2014 Dec;20 Suppl 6:11-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25482964</ArticleId></ArticleIdList></Reference><Reference><Citation>Virulence. 2013 Aug 15;4(6):537-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23863601</ArticleId></ArticleIdList></Reference><Reference><Citation>Respir Res. 2009 Jun 01;10:43</Citation><ArticleIdList><ArticleId IdType="pubmed">19486528</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Virol. 2011 Oct;1(4):226-32</Citation><ArticleIdList><ArticleId IdType="pubmed">22440781</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 2011 May 27;34(5):637-50</Citation><ArticleIdList><ArticleId IdType="pubmed">21616434</ArticleId></ArticleIdList></Reference><Reference><Citation>J Inflamm (Lond). 2005 Nov 29;2:16</Citation><ArticleIdList><ArticleId IdType="pubmed">16316467</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods. 2001 Dec;25(4):402-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2012 Jan;86(2):667-78</Citation><ArticleIdList><ArticleId IdType="pubmed">22072765</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 2007 Nov 1;110(9):3245-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17660379</ArticleId></ArticleIdList></Reference><Reference><Citation>Microb Pathog. 1991 Feb;10(2):105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">1890949</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Mar 27;10(3):e0120075</Citation><ArticleIdList><ArticleId IdType="pubmed">25816133</ArticleId></ArticleIdList></Reference><Reference><Citation>J Allergy Clin Immunol. 2011 Dec;128(6):1216-1224.e11</Citation><ArticleIdList><ArticleId IdType="pubmed">21996340</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2001 Oct 18;413(6857):732-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11607032</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2009 Apr;1788(4):864-71</Citation><ArticleIdList><ArticleId IdType="pubmed">18952050</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Immunol. 2011 Feb;30(1):16-34</Citation><ArticleIdList><ArticleId IdType="pubmed">21235323</ArticleId></ArticleIdList></Reference><Reference><Citation>J Interferon Cytokine Res. 2014 Jun;34(6):427-36</Citation><ArticleIdList><ArticleId IdType="pubmed">24905199</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Jun 03;8(6):e63776</Citation><ArticleIdList><ArticleId IdType="pubmed">23755110</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1999 Oct 4;147(1):185-94</Citation><ArticleIdList><ArticleId IdType="pubmed">10508865</ArticleId></ArticleIdList></Reference><Reference><Citation>Thromb Haemost. 2013 Mar;109(3):407-15</Citation><ArticleIdList><ArticleId IdType="pubmed">23389236</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(10):e47323</Citation><ArticleIdList><ArticleId IdType="pubmed">23115643</ArticleId></ArticleIdList></Reference><Reference><Citation>Respir Res. 2007 Oct 30;8:75</Citation><ArticleIdList><ArticleId IdType="pubmed">17971210</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Apr 23;8(4):e62576</Citation><ArticleIdList><ArticleId IdType="pubmed">23626836</ArticleId></ArticleIdList></Reference><Reference><Citation>Tissue Barriers. 2015 Apr 03;3(1-2):e974448</Citation><ArticleIdList><ArticleId IdType="pubmed">25838980</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2011 Apr 15;186(8):4794-804</Citation><ArticleIdList><ArticleId IdType="pubmed">21398612</ArticleId></ArticleIdList></Reference><Reference><Citation>Future Virol. 2014 Sep;9(9):811-829</Citation><ArticleIdList><ArticleId IdType="pubmed">25620999</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Immunol. 2006 Jul;26(4):406-16</Citation><ArticleIdList><ArticleId IdType="pubmed">16786433</ArticleId></ArticleIdList></Reference><Reference><Citation>Essays Biochem. 2012;53:41-54</Citation><ArticleIdList><ArticleId IdType="pubmed">22928507</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Virol. 2014 Aug;7:134-40</Citation><ArticleIdList><ArticleId IdType="pubmed">25063986</ArticleId></ArticleIdList></Reference><Reference><Citation>J Intern Med. 2015 Mar;277(3):277-93</Citation><ArticleIdList><ArticleId IdType="pubmed">25418337</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Med Virol. 2015 Jan;25(1):50-67</Citation><ArticleIdList><ArticleId IdType="pubmed">25430853</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2010 Nov 04;6(11):e1001178</Citation><ArticleIdList><ArticleId IdType="pubmed">21079690</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000199 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000199 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:27504984
|texte= Poly(I:C) Induces Human Lung Endothelial Barrier Dysfunction by Disrupting Tight Junction Expression of Claudin-5.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:27504984" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |